Employees: 1,611
Size ASKA Pharmaceutical (4886.T) is a Japan Health Care company (Pharmaceuticals: Major) with a market value of $354M, the 1250th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥2,125 on 18 Nov 2026.
Performance Over six months the shares fell 24.3%, against -22.1% for the median peer and -1.4% for the Japan market (cap-weighted) — 8th lowest of 20 in its peer set.
Growth Revenue grew 10.9% over the last twelve months (peer median +1.0%).
Valuation It trades at 12.9× forward earnings against a peer median of 28.1× (2nd cheapest of 7).
Next results Next results expected around 8 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | n/a | ¥71.1B | ¥64.1B | ¥62.8B | ¥60.5B |
| Revenue growth | — | +11% | +2% | +4% | — |
| Gross profit | n/a | ¥34.1B | ¥31.3B | ¥30.7B | ¥28.6B |
| EBITDA | n/a | ¥8.92B | ¥7.58B | ¥9.16B | ¥8.24B |
| Net income | ¥5.21B | ¥5.42B | ¥5.10B | ¥7.54B | ¥4.24B |
| Free cash flow | n/a | ¥3.75B | -¥475M | ¥166M | ¥2.89B |
| Capital expenditure | n/a | ¥2.87B | ¥3.56B | ¥1.45B | ¥746M |
| Total debt | ¥9.91B | ¥11.4B | ¥10.9B | ¥9.48B | ¥12.6B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 4886.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.9% | -9.8% | 2nd highest of 20 |
| 6-month return | -24.3% | -22.1% | 8th lowest of 20 |
| Distance from 52-week high | -30.2% | -38.5% | 7th highest of 21 |
| Revenue growth (TTM) | +10.9% | +1.0% | 4th highest of 19 |
| Forward P/E | 12.9× | 28.1× | 2nd cheapest of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| ASKA Pharmaceutical 4886.T | Japan | $354M | -24% | +11% | n/a | 12.9× | n/a | n/a |
| Anhui Fengyuan Pharmaceutical 000153.SZ | China | $355M | -17% | -24% | 3% | n/a | 3.6% | +3.1% |
| Guizhou Yibai Pharmaceutical 600594.SS | China | $351M | -23% | -26% | -15% | n/a | 8.0% | -11.3% |
| KYORIN Pharmaceutical 4569.T | Japan | $360M | -22% | -6% | 2% | 35.5× | 6.7% | +4.2% |
| Unichem Laboratories UNICHEMLAB.NS | India | $361M | +28% | +6% | 5% | n/a | n/a | n/a |
| Tuoxin Pharmaceutical 301089.SZ | China | $363M | -28% | +17% | -20% | n/a | n/a | n/a |
| Pharmicell 005690.KS | South Korea | $364M | -55% | +46% | 32% | 8.2× | -7.9% | +24.8% |
| Guangdong Lifestrong Pharmacy 301111.SZ | China | $368M | -33% | +7% | -2% | n/a | n/a | n/a |
| 6467 6467.TW | Taiwan | $368M | n/a | n/a | -2,618% | n/a | n/a | n/a |
| MapLight Therapeutics MPLT | United States | $370M | -76% | n/a | n/a | n/a | n/a | n/a |
| Tiansheng Pharmaceutical 002872.SZ | China | $371M | -1% | -1% | -13% | n/a | 22.2% | -15.7% |
| ARS Pharmaceuticals SPRY | United States | $371M | -53% | -14% | -162% | n/a | n/a | n/a |
| Puma Biotechnology PBYI | United States | $373M | +3% | +9% | 11% | 19.0× | 0.1% | +0.3% |
| Jiangsu Bioperfectus Technologies 688399.SS | China | $374M | -51% | -8% | -23% | n/a | n/a | n/a |
| Solara Active Pharma Sciences SOLARA.NS | India | $334M | +12% | +27% | 8% | 20.7× | 38.3% | -3.2% |
| BioDlink International 1875.HK | Hong Kong | $334M | -24% | -51% | -31% | 288.2× | n/a | n/a |
| Mayne Pharma MYX.AX | Australia | $333M | +155% | -6% | -14% | n/a | 19.0% | -0.9% |
| Kingchem (Liaoning) Life Science 301509.SZ | China | $333M | -28% | +3% | 6% | n/a | 9.2% | +6.5% |
| Opus Genetics IRD | United States | $379M | -22% | -46% | -778% | n/a | n/a | n/a |
| JCR Pharmaceuticals 4552.T | Japan | $379M | -5% | +3% | -14% | 398.3× | n/a | n/a |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | -1% | +5% | 22% | n/a | -11.5% | +10.3% |